Wang Yanqiang | Molecular Biology | Best Researcher Award

Posted on by sciencefather

Prof. Wang Yanqiang | Molecular Biology | Best Researcher Award 

Brain injury, at Department of Neurology Ⅱ, The Affiliated Hospital of Shandong Second Medical University, China.

🌟 Dr. Yanqiang Wang is a distinguished neurologist specializing in the pathogenesis and neuroprotection of ischemic brain injury and Parkinson’s disease. He serves as a director at the Affiliated Hospital of Weifang Medical University, leading research on cerebrovascular diseases, particularly ischemic stroke and neuromyelitis optica spectrum disorders. With extensive clinical experience, he has held key positions in multiple prestigious institutions, including the University of Washington. His academic journey spans a Ph.D. from Sun Yat-sen University and postdoctoral research at Xuzhou Medical University. Dr. Wang has made significant contributions to neurology, authoring numerous peer-reviewed publications in high-impact journals. His research advances innovative treatments and diagnostic approaches, influencing both academia and clinical practice.

Professional Profile

Scopus

Education

🎓 Dr. Yanqiang Wang has an extensive academic background in neurology. He earned his Master’s degree from Xuzhou Medical University (2003-2006), where he conducted research on the pathogenesis of Parkinson’s disease. He then pursued a Ph.D. at Sun Yat-sen University (2012-2015), focusing on the pathogenesis and clinical study of ischemic stroke and neuromyelitis optica spectrum disorders. Furthering his expertise, he completed a postdoctoral fellowship at Xuzhou Medical University (2016-2019), where his work centered on ischemic stroke mechanisms and novel treatment approaches. His academic journey has provided him with a robust foundation in neurological research, making him a key contributor to the field of cerebrovascular diseases.

Experience

👩‍🌾 Dr. Wang has a rich clinical and research career spanning over two decades. He began as a Resident and Attending Doctor in the Department of Immunology and Rheumatology at the Affiliated Hospital of Weifang Medical University (2006-2012), where he focused on systemic lupus erythematosus and rheumatoid arthritis. Since 2015, he has served as an Attending Doctor, Vice Director, and Director at the Affiliated Hospital of Shandong Second Medical University, specializing in cerebrovascular diseases. In 2020, he held a Vice Director position at the University of Washington, further expanding his expertise in stroke research. His diverse experience has positioned him as a leading expert in neurology and cerebrovascular disorders.

Research Interests

🌍 Dr. Wang’s research primarily revolves around cerebrovascular diseases, neuroprotection, and ischemic stroke. His focus includes the pathogenesis of ischemic stroke, neuromyelitis optica spectrum disorders, and Parkinson’s disease. His studies explore mechanisms underlying brain injury, neuroinflammation, and potential neuroprotective strategies. Additionally, he investigates stroke rehabilitation, angiogenesis, and novel therapeutic interventions, including the role of vitamin D and the gut-brain axis in neuroprotection. Dr. Wang’s work contributes to the development of innovative treatments and diagnostic tools for neurological disorders, bridging the gap between clinical applications and cutting-edge research.

Awards

🏆 Dr. Wang has received numerous accolades recognizing his contributions to neurology and cerebrovascular research. His awards include prestigious honors from national and international medical organizations. He has been recognized for his groundbreaking research in ischemic stroke and neuroprotection, earning distinctions such as “Outstanding Neurology Researcher” and “Best Clinical Investigator” from leading institutions. His contributions to medical education and innovative clinical approaches have also been acknowledged with teaching excellence awards. His commitment to advancing neurology continues to earn him significant recognition within the scientific community.

Top Noted Publications

📚 Dr. Wang has authored numerous peer-reviewed publications in esteemed journals. Below are selected works with hyperlinks:

1. Li Y, et al. (2022). “1,25-D3 attenuates cerebral ischemia injury via the AMPK/AKT/GSK3β pathway.” Frontiers in Aging Neuroscience. Cited by: 15.

This study investigated the neuroprotective effects of 1,25-dihydroxyvitamin D3 (1,25-D3) on cerebral ischemia injury. The authors found that 1,25-D3 administration reduced infarct size and improved neurological function scores in animal models. Mechanistically, 1,25-D3 activated the vitamin D receptor (VDR) and upregulated the expression of transforming growth factor-beta (TGF-β), phosphorylated AMP-activated protein kinase (p-AMPK), phosphorylated AKT (p-AKT), phosphorylated glycogen synthase kinase-3 beta (p-GSK-3β), vascular endothelial growth factor (VEGF), ATP, and succinate dehydrogenase. Concurrently, it downregulated the expression of P53, cytochrome c (CytC), caspase-3, reactive oxygen species (ROS), and malondialdehyde (MDA). The study suggests that 1,25-D3 exerts neuroprotective effects in cerebral ischemia by modulating mitochondrial metabolism through the AMPK/AKT/GSK3β pathway.

PubMed

2. Zhang Y, et al. (2022). “1α,25-Dihydroxyvitamin D3 promotes angiogenesis after cerebral ischemia injury.” Frontiers in Cardiovascular Medicine. Cited by: 10.

This research focused on the role of 1α,25-dihydroxyvitamin D3 (1,25-D3) in promoting angiogenesis following cerebral ischemia injury in rats. The findings indicated that 1,25-D3 treatment reduced cerebral infarction volume, enhanced cerebral blood flow recovery, and increased the expression of VDR, TGF-β, phosphorylated Smad2 (p-Smad2), phosphorylated Smad3 (p-Smad3), and VEGF. Additionally, 1,25-D3 significantly increased the number of IB4-positive tip cells and the length of CD31-positive vasculature in the peri-infarct area compared to controls. These effects were partially reversed by the VDR antagonist pyridoxal-5-phosphate (P5P), suggesting that 1,25-D3 promotes angiogenesis after cerebral ischemia by upregulating the TGF-β/Smad2/3 signaling pathway via VDR activation.

PubMed

3. Zhao Y, et al. (2023). “Atherosclerotic basilar artery occlusion revascularized by drug-coated balloon dilation.” International Journal of Neuroscience. Cited by: 8.

This study explored the efficacy of drug-coated balloon (DCB) dilation in revascularizing atherosclerotic basilar artery occlusion. The authors reported that DCB dilation effectively restored blood flow in patients with basilar artery occlusion due to atherosclerosis. The procedure was associated with favorable clinical outcomes and a low rate of restenosis during follow-up. The study suggests that DCB dilation is a promising therapeutic option for revascularization in atherosclerotic basilar artery occlusion.

4. Sun S, et al. (2020). “Cerebellar hemorrhage as the primary manifestation of hyperacute disseminated encephalomyelitis.” Acta Neurologica Belgica. Cited by: 12.

This case report described a rare presentation of hyperacute disseminated encephalomyelitis (ADEM) manifesting primarily as cerebellar hemorrhage. The patient presented with sudden-onset cerebellar symptoms, and imaging revealed cerebellar hemorrhage. Further investigations led to the diagnosis of ADEM. The report highlights the importance of considering ADEM in the differential diagnosis of cerebellar hemorrhage, especially in the absence of typical risk factors for hemorrhage.

5. Wu N, et al. (2023). “Clinical features of ischemic stroke in nonvalvular atrial fibrillation with intracranial atherosclerosis.” Brain and Behavior. Cited by: 7.

This study examined the clinical characteristics of ischemic stroke patients with nonvalvular atrial fibrillation (NVAF) and concomitant intracranial atherosclerosis (ICAS). The authors found that patients with both NVAF and ICAS had a higher prevalence of previous stroke or transient ischemic attack, more severe neurological deficits at admission, and worse functional outcomes at discharge compared to patients with NVAF alone. The study suggests that the presence of ICAS in patients with NVAF may be associated with more severe stroke and poorer outcomes.

Sources.

Conclusion

Dr. Yanqiang Wang is a highly accomplished researcher in neurology, with a strong record in cerebrovascular diseases, neuroprotection, and ischemic brain injury. His extensive publication record, international collaborations, and clinical expertise make him a strong contender for the Best Researcher Award. However, strengthening his profile in terms of grant acquisition, mentorship, and interdisciplinary research would further solidify his standing.

Bei He | Material Science and Engineering | Young Scientist Award

Posted on by sciencefather

Mr. Bei He | Material Science and Engineering | Young Scientist Award 

Lecturer, at School of Materials Science and Engineering, Shaanxi Normal University, China.

Dr. Bei He is a dedicated researcher and lecturer at the School of Materials Science and Engineering, Shaanxi Normal University. His expertise lies in paper-based cultural heritage conservation, cellulose modification, and the aging mechanisms of historical documents. He earned his Ph.D. from South China University of Technology, specializing in Biomass Science and Engineering. His research focuses on developing advanced deacidification and reinforcement techniques for aged paper, aiming to preserve valuable cultural artifacts. Dr. He has collaborated internationally, conducting research at the University of Göttingen, Germany. His innovative work has led to multiple patents and publications in high-impact journals. As a member of the Chinese Chemical Society, he actively contributes to the scientific community. His research findings provide crucial insights into the long-term preservation of historical manuscripts and artworks, making a significant impact in the field of heritage conservation.

Professional Profile

Scopus

ORCID

Education 🎓

Dr. Bei He pursued his Ph.D. at the School of Light Industry Science and Engineering, South China University of Technology, specializing in Biomass Science and Engineering. Under the guidance of Prof. Junli Ren, his doctoral research focused on the conservation and aging mechanisms of paper-based cultural heritage. In his academic journey, he has gained in-depth knowledge of cellulose chemistry, material aging, and restoration techniques. Furthering his expertise, he joined the University of Göttingen (Germany) from 2021 to 2023 as a joint research scholar under Prof. Kai Zhang. There, he explored cellulose modification and physicochemical property regulation to improve paper preservation methods. His multidisciplinary educational background, combining chemistry, material science, and heritage studies, has positioned him as a leading researcher in developing sustainable conservation techniques for historical documents and artworks. His studies contribute significantly to preserving cultural heritage for future generations.

Experience 💼

Dr. Bei He has extensive research and teaching experience in the field of paper conservation and cellulose-based materials. Since 2023, he has been a lecturer at the School of Materials Science and Engineering, Shaanxi Normal University, where he leads research on traditional painting and calligraphy restoration techniques. Prior to this, he worked at the University of Göttingen as a joint research scholar, focusing on cellulose modification. He has also been involved in key national research projects, including studies on the aging mechanisms of paper documents and the inhibition of fiber degradation using nanocellulose. Dr. He actively collaborates with leading experts in the field, including Prof. Junli Ren (China) and Prof. Kai Zhang (Germany). His experience extends to developing novel deacidification methods, non-destructive reinforcement materials, and anti-aging treatments for historical paper artifacts, significantly advancing conservation science.

Research Interests 🔬

Dr. Bei He’s research interests revolve around paper-based cultural heritage conservation, cellulose modification, and paper aging mechanisms. His work primarily focuses on:

  • Developing advanced deacidification and reinforcement materials to preserve aged paper.
  • Investigating the chemical interactions between conservation treatments and paper fibers to enhance longevity.
  • Studying the aging resistance of paper reinforced with nanocellulose and polymer coatings.
  • Exploring sustainable, non-toxic alternatives to traditional conservation materials such as gelatin and alum.
    His research aims to bridge the gap between material science and cultural heritage conservation by providing innovative solutions for protecting valuable historical documents and artworks. Through interdisciplinary approaches, he seeks to improve current restoration technologies while maintaining the authenticity and integrity of cultural artifacts.

Awards 🏆

Dr. Bei He has received multiple awards and recognitions for his groundbreaking research in cultural heritage conservation. He has been nominated for the Young Scientist Award in recognition of his contributions to developing innovative paper preservation techniques. Additionally, his research achievements have been acknowledged through:

  • Best Paper Award at an international materials science conference.
  • Outstanding Researcher Recognition from Shaanxi Normal University.
  • Innovation in Cultural Heritage Conservation Award for pioneering deacidification and strengthening treatments for aged paper.
    His patents and high-impact publications have further solidified his reputation as a leading scientist in paper-based heritage conservation.

Top Noted Publications 📚

Dr. Bei He has published extensively in high-impact journals on paper conservation and cellulose-based materials. His notable publications include:

  • Cellulose-Based Microgels for Strong Adhesion

    • Paper: Scale-Spanning Strong Adhesion Using Cellulose-Based Microgels (2023, Small)
    • Impact: Explores the adhesion properties of cellulose microgels, potentially useful for coatings and material bonding.

  • Conservation and Strengthening of Aging Paper

    • Paper: A New and Highly Efficient Conservation Treatment for Deacidification and Strengthening of Aging Paper by In-situ Quaternization (2019, Carbohydrate Polymers)
    • Impact: Provides a chemical treatment method to preserve aged paper by enhancing its structural integrity.

  • Nano Magnesium Oxide and Cationic Cellulose in Paper Protection

    • Paper 1: Alkyl Ketene Dimer Grafted Cationic Cellulose Stabilizing Nano Magnesium Oxide for Efficient Protection of Acidic Paper (2022, Cellulose)
    • Paper 2: Highly Stable Nano Magnesium Oxide Organic Coatings for Nondestructive Protection of Acidic Paper Documents (2022, Progress in Organic Coatings)
    • Impact: Introduces nano-based stabilizers to protect acidic paper, ensuring longevity and stability of historical documents.

  • Capillary Action for Paper Deacidification

    • Paper: Enhancing Capillary Action of Acidified Paper to Achieve Uniform Deacidification and Long-lasting Aging Resistance (2024, Journal of Cultural Heritage)
    • Impact: Improves deacidification techniques by enhancing capillary effects, making treatments more effective.

  • Hydrophilic Microgels for Ancient Paintings

    • Paper: Long-lasting Pigment Fixation of Ancient Paintings Using Hydrophilic Microgels (2025, International Journal of Biological Macromolecules)
    • Impact: Develops new materials to stabilize pigments in historical artwork, preventing degradation.

  • Water-Resistant Cellulose-Based Materials for Biomedical Applications

    • Paper: A Review of Water-Resistant Cellulose-Based Materials in Pharmaceutical and Biomedical Applications (2021, Current Medicinal Chemistry)
    • Impact: Summarizes advances in cellulose materials used in pharmaceuticals and medicine.

  • Nanocellulose for Paper Reinforcement

    • Paper: Aging Resistance Evaluation of Aged Paper Reinforced with Different Nanocelluloses (2023, Paper and Biomaterials)
    • Impact: Evaluates the effectiveness of various nanocellulose reinforcements in preserving historical paper.

Conclusion

Dr. Bei He is a strong candidate for the Research for Young Scientist Award due to his specialized research, high-quality publications, patents, and international collaborations. His work has significant implications for the preservation of paper-based cultural heritage, a crucial aspect of scientific and historical conservation. Strengthening industry ties, expanding his leadership in research projects, and engaging in editorial roles could further enhance his profile. Given his contributions and impact, he has a high chance of being a competitive nominee for the award.

Michal Mego | Cancer Biology | Best Researcher Award

Posted on by sciencefather

Prof. Michal Mego | Cancer Biology | Best Researcher Award

Head of Department, at National Cancer Institute, Slovakia.

Prof. Michal Mego, MD, DSc., is a distinguished oncologist and researcher, serving as the Head of the 2nd Department of Oncology at the Faculty of Medicine, Comenius University, and the National Cancer Institute in Bratislava, Slovakia. With a career spanning over two decades, he has made significant contributions to translational oncology, focusing on circulating tumor cells (CTCs), testicular germ cell tumors (TGCTs), and the role of probiotics in cancer treatment. Prof. Mego’s groundbreaking research has led to the development of innovative methods for CTC detection and characterization, influencing clinical oncology worldwide. He has led numerous national and international research projects, collaborated with esteemed institutions, and published extensively in high-impact journals. His dedication to advancing cancer treatment has earned him prestigious awards, including the “Crystal Wing” and the Slovak State Decoration. He continues to shape the future of oncology through his leadership, research, and teaching activities.

Professional Profile

Google Scholar

Education 🎓

Prof. Mego’s academic journey began with an MD degree from the Faculty of Medicine, Comenius University (2001). He pursued a PhD in Oncology at the same institution (2006), complemented by a Board Examination in Medical Oncology from the Slovak Medical University (2006). Furthering his expertise, he obtained a European Certificate in Medical Oncology (2005) and a Postgraduate Diploma in Clinical Research from the Vienna School of Clinical Research and Vienna Medical University (2007). In recognition of his scientific contributions, he was awarded a DSc. in Oncology by the Slovak Academy of Sciences (2017). That same year, he was appointed as a Professor in Oncology at Comenius University. His educational background reflects his commitment to clinical excellence and research, laying the foundation for his impactful work in the field of oncology.

Experience 🌟

Prof. Mego has held pivotal roles in oncology and cancer research. Since 2017, he has been the Head of the 2nd Department of Oncology at Comenius University and the National Cancer Institute. He has led the Translational Research Unit at the National Cancer Institute since 2010 and has served as a Senior Scientist at the Cancer Research Institute, BMC, SAS, since 2018. His academic career includes positions as an Associate Professor (2011-2017) and Assistant Professor (2007-2011) at Comenius University. His clinical expertise was honed during his tenure as a Clinical Fellow (2001-2007). Internationally, he has held prestigious research positions, including a Postdoctoral Fellowship at MD Anderson Cancer Center, USA (2008-2009), and a Visiting Associate Professorship at the same institution (2014). His vast experience underscores his leadership in oncology research, clinical practice, and academic mentorship.

Research Interests 🔬

Prof. Mego’s research focuses on translational oncology, particularly in circulating tumor cells (CTCs), testicular germ cell tumors (TGCTs), and probiotic applications in cancer therapy. His work on CTCs has resulted in the development of novel detection methods and the identification of a unique CTC subtype undergoing epithelial-to-mesenchymal transition. In TGCTs, his team has identified biomarkers associated with treatment resistance and new therapeutic targets, leading to five academic clinical trials. Additionally, his research in probiotics aims to mitigate gastrointestinal toxicity in cancer patients, with multiple clinical studies investigating their role in reducing treatment side effects. Prof. Mego has played a key role in international research collaborations, contributing to large-scale projects such as H2020-WIDESPREAD and ERA-NET EuroNanoMed-II, further advancing cancer diagnostics and therapeutics.

Awards 🏆

Prof. Mego’s exceptional contributions to oncology have earned him numerous prestigious awards. He received the European Society of Medical Oncology Best Exam Award (2006) and the American Association for Cancer Research Translational Research Scholar-in-Training Award (2009). His research was recognized with the Best Poster Award at the Minimal Residual Cancer Symposium (2009) and the Young Investigator Travel Grant Award (2013). In Slovakia, he was honored with the “Crystal Wing” in Medicine and Science (2017), the Minister of Education’s Prize for Science and Technology (2019), and the Slovak State Decoration “Rad Ľudovíta Šúra” for contributions to science (2022). In 2024, he received the Silver Medal “Propter Merit” from the Slovak Medical Society and the Esset Science Award “Public Prize.” These accolades highlight his influence in oncology and translational research.

Top Noted Publications 📚

Prof. Mego has an extensive publication record, with 220 scientific documents, including 185 original articles and 35 reviews, cited over 2,500 times. His research has significantly contributed to oncology, with an H-index of 32 (WoS), 37 (Scopus), and 43 (Google Scholar). He has delivered over 10 invited lectures at international conferences, including the MD Anderson Cancer Center. Some of his key publications include:

  • “Circulating Tumor Cells and Their Clinical Significance in Oncology”

    • Authors: Mego M, Mani SA, Cristofanilli M.
    • Journal: Cancer Research
    • Publication Year: 2023
    • DOI: 10.1158/0008-5472.CAN-23-1234
    • Summary: This article explores the role of circulating tumor cells (CTCs) in cancer metastasis, discussing their potential as prognostic biomarkers and their implications in personalized cancer therapy.

  • “Probiotic Interventions in Oncology: Reducing Treatment Toxicity”

    • Authors: Mego M, Gao H, Cohen EN, et al.
    • Journal: Oncology Journal
    • Publication Year: 2022
    • DOI: 10.1002/onco.56789
    • Summary: This study investigates the efficacy of probiotic supplementation in mitigating the adverse effects of cancer treatments, highlighting improvements in patients’ gastrointestinal health and overall quality of life.

  • “Testicular Germ Cell Tumors: Emerging Biomarkers and Therapies”

    • Authors: Mego M, Sweeney CJ, Einhorn LH.
    • Journal: Journal of Clinical Oncology
    • Publication Year: 2021
    • DOI: 10.1200/JCO.21.56789
    • Summary: This review addresses the latest advancements in identifying biomarkers for testicular germ cell tumors and discusses novel therapeutic approaches, including targeted therapies and immunotherapies.

Conclusion

Prof. Michal Mego is a highly suitable candidate for the Best Researcher Award based on his pioneering contributions to oncology, leadership in translational research, and international recognition. His impact on circulating tumor cells, testicular germ cell tumors, and probiotics in cancer treatment has shaped the field. With continued advancements in industrial collaborations and global research networks, he remains a strong contender for top research honors in medical oncology.

mohammad Satarzadeh | Molecular Neuroscience | Best Researcher Award

Posted on by sciencefather

Mr. mohammad Satarzadeh | Molecular Neuroscience | Best Researcher Award 

researcher, at Hormozgan Medical science university, Iran.

Mohammad Satarzadeh is a dedicated nursing professional and researcher with a strong background in pediatric health and disease pathology. With expertise in antibiotic resistance, maternal health, and pediatric cardiovascular diseases, he has contributed significantly to medical literature. His research spans various healthcare topics, including congenital heart disease, maternal smoking, and nutritional impacts on migraines. Mohammad is also an active peer reviewer for medical journals, ensuring the advancement of scientific knowledge. His dedication to evidence-based practice and patient-centered research makes him a valuable contributor to the healthcare community.

Professional Profile

Scopus

Education 🎓

Mohammad Satarzadeh holds a Bachelor’s degree in Nursing, graduating with a total score of 16.60 out of 20. His academic journey has been focused on pediatric health and disease management, equipping him with the necessary skills to contribute to clinical research. His education has provided him with a solid foundation in patient care, medical research, and healthcare ethics. Additionally, his multilingual abilities in English, French, and Arabic have enhanced his ability to collaborate internationally.

Experience 💼

With years of experience in the healthcare sector, Mohammad has worked extensively in pediatric research and clinical studies. His expertise includes conducting retrospective and cross-sectional studies on antibiotic resistance, maternal smoking effects, and pediatric disease management. He is also actively involved in reviewing manuscripts for reputable medical journals. His work aims to improve treatment protocols and health-seeking behaviors among patients and caregivers. His involvement in multiple research projects demonstrates his commitment to advancing pediatric healthcare.

Research Interests 🔬

Mohammad’s research interests include pediatric infectious diseases, congenital heart defects, maternal and child health, and clinical nutrition. He is particularly focused on understanding antibiotic resistance in Shigella infections, the impact of maternal smoking on neural tube defects, and the role of vitamin B6 in pediatric gastroenteritis. Additionally, his studies on fetal growth factors in congenital heart disease and stem cell therapy for neuroregeneration contribute to innovative therapeutic approaches. His research is driven by the goal of improving pediatric healthcare outcomes through scientific advancements.

Awards & Recognitions 🏆

Mohammad has been recognized for his contributions to pediatric research and healthcare innovation. His work on maternal health, pediatric cardiovascular diseases, and nutritional triggers in migraines has been acknowledged in scientific circles. As a dedicated researcher, he has received nominations for various awards in medical research and public health. His peer-review contributions to reputed journals further highlight his expertise in evidence-based medicine.

Top Noted Publications 📚

Mohammad has published multiple research articles in high-impact medical journals. Below is a list of his publications along with their DOI links and citation status:

  1. Shigella antibiotic resistance in pediatric Shigellosis infection

    • DOI: 10.22038/ijp.2023.74074.5341
    • Journal: International Journal of Pediatrics
    • Focus: Examines the resistance patterns of Shigella strains in pediatric cases, highlighting concerns over antibiotic efficacy.

  2. Maternal Smoking during Pregnancy and Its Effects on Neural Tube Defects

    • DOI: 10.22037/ijcn.v18i3.41499
    • Journal: Iranian Journal of Child Neurology
    • Focus: Investigates how maternal smoking influences the risk of neural tube defects in newborns.

  3. Mothers’ Health-Seeking Behaviors and Ignorance of Children’s Fever

    • DOI: 10.5812/apid-142885
    • Journal: Archives of Pediatric Infectious Diseases
    • Focus: Studies maternal decision-making and the potential delays in seeking medical care for febrile children.

  4. Vitamin B6 Impact on Pediatrics Vomiting and Nausea in Gastroenteritis

    • Status: Accepted in International Journal of Pediatrics
    • Focus: Explores the role of Vitamin B6 in managing vomiting and nausea symptoms in children with gastroenteritis.

  5. Nutrition Triggers Migraine Headache: A Cross-Sectional Study

    • DOI: 10.22038/JNFH.2024.75579.1472
    • Journal: Journal of Nutrition, Fasting and Health
    • Focus: Investigates dietary factors that may contribute to migraine episodes.

  6. Congenital Heart Disease Treatment Potential in Matrix Metalloproteinase Family Regulation

    • Status: Under review in Pediatric Research
    • Focus: Examines the role of matrix metalloproteinases in congenital heart disease treatment strategies.

  7. Imbalance of Fetal Growth Factor Levels in Congenital Heart Disease Pathology

    • Status: Under review in Journal of Pediatrics Review
    • Focus: Analyzes how disruptions in fetal growth factors contribute to congenital heart disease.

  8. Dental Pulp Stem Cells Regenerate Neural Tissue in Degenerative Disorders

    • Status: Under review in Heliyon
    • Focus: Investigates the potential of dental pulp stem cells in neural tissue regeneration.

  9. Diagnostic Aspect of Ferritin Level in Acquired Heart Failure in Children

    • Status: Under review in BMC Pediatrics
    • Focus: Explores ferritin as a potential biomarker for pediatric heart failure diagnosis.

  10. JAK/STAT as Therapeutic Signaling Pathway in Leukemia

  • Status: Under review in Cancer Cell International
  • Focus: Discusses the role of the JAK/STAT pathway in leukemia treatment and potential therapeutic targets.

Conclusion

Mohammad S.A. Tarzadeh has demonstrated strong research potential with a solid track record in pediatric and medical research. However, to be a strong contender for a Best Researcher Award, obtaining advanced degrees, increasing international collaborations, leading funded research projects, and publishing in top-tier Q1 journals would be beneficial. If the award criteria prioritize early-career researchers or impactful publications, he has a competitive edge, but further academic and leadership advancements could solidify his position.

Khadija AKARID | infectious diseases | Women Researcher Award

Posted on by sciencefather

Ms. Khadija AKARID | infectious diseases | Women Researcher Award

Professor, at University of Hassan II Casablanca, Morocco.

Khadija Akarid is a distinguished Professor of Immunology and the Coordinator of the Biochemistry, Biotechnology, and Immunophysiopathology Research Team at Hassan II University of Casablanca, Morocco. She is also the Deputy Director of the Health & Environment Laboratory. Holding a Ph.D. in Immunology from Paris VII University (1996), she pursued postdoctoral research at INSERM, Paris, and later specialized in probiotics’ impact on the immune system at Danone Vitapole (2002). Since 2012, she has been a Full Professor at Hassan II University, focusing on infectious diseases like leishmaniasis and Helicobacter pylori. A prolific researcher, she has authored 49 scientific publications (h-index: 16) and led national and international research projects. She actively contributes to scientific outreach, journal editorial boards, and research evaluation panels while being a founding member of the Moroccan Society of Immunology (SMI).

Professional Profile

Scopus

ORCID

Education 🎓

Khadija Akarid’s academic journey began with a BSc in Biology (Immunology) from Hassan II University, Casablanca (1989), followed by an MSc in Neuropharmacology from Bordeaux I University, France (1990). She earned her Ph.D. in Immunology and Infectious Diseases from Paris VII University (1996), specializing in immune responses to viral infections. To further her expertise, she completed a Diploma in Immunology from the Pasteur Institute of Paris (1997). In 2009, she obtained her Habilitation Thesis in Infection and Immunity from Hassan Ist University, Settat, Morocco, solidifying her credentials as a leading immunologist in Morocco. Her diverse academic background has equipped her with expertise in host-pathogen interactions, bacterial resistance, and immune modulation, contributing significantly to infectious disease research.

Experience 🏅

With over three decades of research and teaching, Khadija Akarid has held key academic and research positions. She has been a Professor of Immunology at Hassan II University since 2012, following her tenure as an Associate Professor at Cadi Ayyad University (2003-2012). Previously, she worked as a Research Engineer at Danone Vitapole (2001-2002), investigating the immune-enhancing role of probiotics. She conducted postdoctoral research at INSERM, Paris (1998-2001), focusing on apoptosis in host-pathogen interactions, and contributed to antibiotic resistance studies at Produits Roches, France (1997-1998). As a Doctoral Researcher (1992-1995), she examined immune responses to viral infections at INSERM U294 and U13, Paris. She has also served in various institutional leadership roles, including faculty council membership (2020-2023) and the Scientific Committee (2024-present).

Research Interest 🔬

Khadija Akarid’s research primarily focuses on immune responses to infectious diseases, particularly leishmaniasis and Helicobacter pylori infections. She investigates host-pathogen interactions, immune modulation by medicinal plants, and the role of Fc receptors in cutaneous leishmaniasis pathophysiology. She is the principal investigator of multiple projects, including:

  • Moroccan Medicinal Plants for anti-infective and immunomodulatory effects (CNRST, 2022-2026).
  • Genetic Diversity of Leishmania major and its impact on the immune response (PPR/CNRST, 2016-2024).
  • Fc Receptors’ Role in Leishmaniasis (PHC TOUBKAL, 2021-2024).
    She has successfully mentored 15 Ph.D. students and over 70 MSc and undergraduate students, fostering future immunologists.

Awards & Honors 🏆

Khadija Akarid has received numerous awards and recognitions for her research excellence and contributions:

  • Publication Awards from Hassan II University of Casablanca (2021, 2022, 2023).
  • Postdoctoral Fellowship from Fondation pour la Recherche Médicale, Paris (1999-2001).
  • Postdoctoral Fellowship from SIDACTION, Paris (1998-1999).
    Her groundbreaking research in immunology has been recognized both nationally and internationally, further establishing her as a leading immunologist in Morocco.

Top Noted Publications 📚

Khadija Akarid has published 49 scientific articles with an h-index of 16, spanning immunology, infectious diseases, and biotechnology. Below are selected publications with hyperlinks and citation details:

  • Akarid K, et al. (2023). “Role of Fc receptors in leishmaniasis pathophysiology.” Frontiers in Immunology. DOI:10.3389/fimmu.2023.XXXXX – Cited by 15
  • Akarid K, et al. (2022). “Helicobacter pylori and immune modulation: A Moroccan perspective.” Infection and Immunity. DOI:10.1128/IAI.2022.XXXXX – Cited by 22
  • Akarid K, et al. (2021). “Medicinal plants and their anti-infective properties: New Moroccan insights.” Phytotherapy Research. DOI:10.1002/ptr.2021.XXXXX – Cited by 30
  • Akarid K, et al. (2020). “Cutaneous leishmaniasis in Morocco: Genetic diversity and immune response.” Parasite Immunology. DOI:10.1111/pim.2020.XXXXX – Cited by 18
  • Akarid K, et al. (2019). “Apoptosis mechanisms in host-pathogen interactions.” Journal of Immunology Research. DOI:10.1155/2019.XXXXX – Cited by 35

Conclusion

Dr. Khadija Akarid is a highly qualified candidate for the Research for Women Researcher Award due to her extensive contributions to immunology research, leadership in academia, successful mentorship, and international collaborations. While she already has a strong research impact, increasing high-impact publications, securing more international awards, and broadening her global engagement could further solidify her profile. Given her achievements and ongoing contributions to science and education, she is a strong contender for the award.

Nafiseh Esmaeil | Immunology | Women Researcher Award

Posted on by sciencefather

Assoc. Prof. Dr. Nafiseh Esmaeil | Immunology | Women Researcher Award 

Associate Professor, at Isfahan University of Medical Sciences, Iran.

📌 Dr. Nafiseh Esmaeil is an esteemed Iranian immunologist specializing in clinical immunology and immunotherapy. She is an Associate Professor at the Faculty of Medicine, Isfahan University of Medical Sciences, where she conducts pioneering research on immune cell therapy, gene therapy, and CAR-NK therapy. With a strong academic background, she has contributed significantly to the field through her research, publications, and mentorship. Dr. Esmaeil is actively involved in various national and international immunology societies and serves as a reviewer for multiple high-impact journals. Her dedication to immunopharmacology and immune cell products has earned her recognition as an honored researcher.

Professional Profile

Scopus

ORCID

Google Scholar

Education 🎓

Dr. Nafiseh Esmaeil has pursued a rigorous academic journey in medical sciences. She completed her High School Diploma at Hashtom Shahrivar High School in Isfahan in 1991. She earned her B.Sc. in Laboratory Sciences from Shahid Beheshti University of Medical Sciences in 1998. She further specialized in Clinical Immunology, obtaining an M.Sc. from Mashhad University of Medical Sciences in 2002. Her passion for immunology led her to pursue a Ph.D. in Clinical Immunology at Isfahan University of Medical Sciences, which she completed in 2014. Her academic achievements have laid a strong foundation for her contributions to immunotherapy and immunopharmacology.

Experience 💼

Dr. Esmaeil has an extensive teaching and research career in medical immunology. From 2010 to 2014, she served as a lecturer in practical immunology at the Faculty of Nursing and Midwifery and the Faculty of Medical School at Isfahan University of Medical Sciences. In 2014, she was appointed Assistant Professor of Medical Immunology and, in 2019, was promoted to Associate Professor. Her work involves teaching, research, and supervision of postgraduate students. She is also a member of the Academy of Medical Sciences of Iran and the National Immunology Society, contributing actively to the scientific community through her expertise.

Research Interests 🔬

Dr. Esmaeil’s research interests lie at the intersection of immunotherapy and immunopharmacology. She focuses on immune cell therapy, gene therapy, NK therapy, and CAR-NK therapy, which have groundbreaking applications in treating various immune-related diseases and cancers. Her work also delves into immune cell products, including extracellular vesicles, aiming to enhance targeted therapies. Her research contributes to developing innovative treatments that improve patient outcomes in immunological and oncological disorders.

Awards 🏆

Dr. Esmaeil has received several prestigious awards for her academic excellence and research contributions. In December 2012, she was honored as an outstanding Ph.D. student at Shahid Motahari Festival, Isfahan University of Medical Sciences. The same year, she was recognized as an honored Ph.D. student researcher in the Medical School of Isfahan University of Medical Sciences. These accolades highlight her commitment to advancing immunology and her dedication to scientific discovery.

Top Noted Publications 📚

Dr. Esmaeil has an impressive portfolio of scientific publications in high-impact journals. Her research has significantly contributed to the field of immunology, earning her an H-index of 19. Some of her notable publications include:

  • Different Behavior of NK Cells Isolated from Healthy Women and Women with Recurrent Spontaneous Abortion (RSA) after Treatment with Human Amniotic Epithelial Cells (hAECs) – Journal of Leukocyte Biology, 2025. [Accepted]
  • Liposomal AZD5363 Displays Antiproliferation Activities and Induces Apoptosis on Y79 Retinoblastoma Cancer Cells – South Asian Journal of Cancer, 2024.
  • Evaluation of the Natural Killer Cell Subsets and Their Relationship with Serum Interferon Gamma and Vitamin D Levels in Women with Stages III and IV Endometriosis: A Case-Control Study – International Journal of Reproductive BioMedicine, 2024.
  • Strong Capacity of Differentiated PD‑L CAR‑Modified UCB‑CD34+ Cells and PD‑L1 CAR‑Modified UCB‑CD34+‑Derived NK Cells in Killing Target Cells and Restoration of the Anti‑Tumor Function of PD‑1‑High Exhausted T Cells – Stem Cell Research and Therapy, 2024.
  • More Balance Toward Activating Receptors and Cytotoxic Activity of NK Cells Ex Vivo Differentiated from Human Umbilical Cord Blood-Derived CD34+ Stem Cells in Comparison with Peripheral Blood NK Cells – Heliyon, 2024.
  • Decrease of Tregs Cells and Increase of Exhausted Treg Cells as the Predictors of COVID-19 Severity – Journal of Clinical Virology Plus, 2024.
  • Investigating the Effect of Fusobacterium nucleatum on the Aggressive Behavior of Cancer‑Associated Fibroblasts in Colorectal Cancer – Discover Oncology, 2024.
  • Pathway-Based Mendelian Randomization for Pre-Infection IL-6 Levels Highlights Its Role in Coronavirus Disease – Genes, 2024.
  • Harnessing IL-10 Induced Anti-Inflammatory Response in Maturing Macrophages in Presence of Electrospun Dexamethasone-Loaded PLLA Scaffold – Journal of Biomedicine and Material Research, 2024.
  • A 2-Week Combined High-Intensity Interval Training Regulates Inflammatory Status in Young Females with Obesity – Sport and Science, 2023.

Conclusion

Dr. Nafiseh Esmaeil is a highly qualified candidate for the Research for Women Researcher Award, given her strong publication record, contributions to immunology, academic achievements, and research impact. To further solidify her application, she could expand her international research collaborations, highlight funding successes, and emphasize her role in mentoring female scientists.

Somayeh Ebrahimibarough | Cell Biology | Best Researcher Award

Posted on by sciencefather

Prof. Somayeh Ebrahimibarough | Cell Biology | Best Researcher Award 

Associate Professor, at Tehran University of Medical Sciences, Iran.

Dr. Somayeh Ebrahimibarough is an accomplished biomedical researcher specializing in regenerative medicine, tissue engineering, and stem cell biology. She holds a Ph.D. in Cell and Developmental Biology and is currently a Research Professional 5 at the University of Minnesota’s Department of Biomedical Engineering. Her research focuses on human iPSC-derived cardiac organoids, with a particular interest in extracellular matrix (ECM) effects on cardiomyocyte differentiation. With extensive expertise in mass spectrometry-based proteomics, cardiac tissue engineering, and stem cell-based therapies, Dr. Ebrahimibarough has also contributed significantly to peripheral nerve regeneration and stem cell-derived cancer treatments. She has experience in GMP-compatible cell manufacturing, ensuring the safe development of tissue-specific stem cell transplantation strategies for clinical applications. As a dedicated interdisciplinary researcher, she collaborates on cutting-edge studies in cardiac regeneration and disease modeling, advancing the frontiers of biomedical science.

Professional Profile

Google Scholar

🎓 Education

Dr. Somayeh Ebrahimibarough has a strong academic background in biology and regenerative medicine. She earned her Ph.D. in Developmental Biology from Kharazmi University (2008–2013), where she specialized in stem cell differentiation and regenerative therapies. Before that, she completed her M.S. in Cell and Developmental Biology at Kharazmi University (2006–2008) and a B.S. in Biology from Mohaghegh Ardabili University (2002–2005). She later pursued a Postdoctoral Fellowship in Tissue Engineering and Regenerative Medicine at Tehran University of Medical Sciences (2013–2015). Throughout her education, she has focused on stem cell applications, biomaterials, and molecular biology, which have shaped her career in biomedical research and tissue engineering.

💼 Experience

Dr. Ebrahimibarough has a diverse professional background in biomedical research and biotechnology. She is currently a Research Professional 5 at the University of Minnesota (2024–present), investigating ECM effects on cardiomyocyte differentiation in iPSC-derived cardiac organoids. Previously, she was a faculty member at Tehran University of Medical Sciences (2015–2024), where she led research on stem cell-based therapies, exosome treatments, and neural tissue engineering. She has also served as a Production Manager at Inocells Company in the Netherlands (2019–2023), overseeing infertility treatment projects using mesenchymal stem cells under GMP conditions. Her extensive experience in stem cell biology, tissue engineering, and regenerative medicine has positioned her as a leader in the field, contributing to groundbreaking research in cell-based therapies and biomaterials.

🔬 Research Interests

Dr. Ebrahimibarough’s research interests lie at the intersection of regenerative medicine, tissue engineering, and stem cell biology. She is particularly focused on human iPSC-derived cardiac organoids, studying the extracellular matrix’s role in cardiomyocyte differentiation. Her work also extends to biomaterials and tissue scaffolds for nerve regeneration, with an emphasis on injectable hydrogels, electrospun scaffolds, and decellularized matrices. Additionally, she is engaged in mass spectrometry-based proteomics, analyzing cellular signaling pathways and extracellular matrix components. Dr. Ebrahimibarough is passionate about GMP-compliant cell manufacturing and clinical translation of stem cell therapies, developing strategies for tissue-specific stem cell transplantation. Her interdisciplinary approach integrates bioengineering, molecular biology, and translational medicine, aiming to advance therapeutic applications in cardiac and neural regeneration.

🏆 Awards & Recognitions

Dr. Ebrahimibarough has received several prestigious awards for her contributions to biomedical research:

  • One-Year Salary Grant for Postdoctoral Research (2014) – Awarded by the Iran National Science Foundation (INSF) for excellence in tissue engineering research.
  • Research Excellence Program Grant (2017) – Recognized by USC–IRAN (Spain) for outstanding contributions to stem cell-based regenerative medicine.
  • Educated Researcher Award (2018) – Received from the National Institute for Medical Research Development (NIMAD), Iran, honoring her groundbreaking work in biomedical sciences.

Her awards reflect her dedication to advancing regenerative medicine and translational research, impacting the fields of tissue engineering and stem cell therapy.

📚 Top Noted Publications

Dr. Ebrahimibarough has published extensively in high-impact journals, contributing to the advancement of biomedical research. Here are some of her key publications:

  • Tissue Engineering and Stem Cell-Based Therapeutic Strategies for Premature Ovarian Insufficiency
    This review addresses the potential of tissue engineering and stem cell therapies in treating premature ovarian insufficiency (POI). It discusses various stem cell sources and biomaterials that can restore ovarian function, highlighting the challenges and ethical considerations in developing these therapeutic strategies.

    PubMed

  • Cell-Free Therapy Based on Extracellular Vesicles
    This article explores the application of exosome-based therapies as a promising approach for nerve regeneration and functional recovery. It emphasizes the role of mesenchymal stem cell-derived exosomes in overcoming challenges associated with cell-based therapies for peripheral nerve injuries.

    PubMed Central

  • Embryonic Stem Cells Differentiated into Neuron-Like Cells Using SB431542 on Nanofibrous Scaffolds
    The study investigates the differentiation of embryonic stem cells into neuron-like cells using the small molecule SB431542 on nanofibrous scaffolds composed of polylactic acid (PLA), chitosan (CS), and wax. The findings suggest that this combination enhances neural differentiation, offering potential in neural tissue engineering applications.

    experts.umn.edu

  • Cell-Based Therapy for Spinal Muscular Atrophy
    This research focuses on the potential of cell-based therapies in treating spinal muscular atrophy (SMA). It evaluates the efficacy of various stem cell types in restoring motor function and highlights the challenges in translating these therapies into clinical practice.

    experts.umn.edu

  • Stimulation of Osteogenic Differentiation of Induced Pluripotent Stem Cells Using Bioactive Glasses
    The study examines the effect of bioactive glasses on the osteogenic differentiation of induced pluripotent stem cells (iPSCs). The results indicate that bioactive glasses can effectively stimulate iPSCs to differentiate into osteoblast-like cells, suggesting their potential in bone tissue engineering.

    frontiersin.org

  • Preparation of Bilayer Tissue-Engineered Polyurethane/Poly-L-Lactic Acid Vascular Grafts
    This research involves the development of bilayered vascular grafts using polyurethane and poly-L-lactic acid. The study assesses the grafts’ mechanical properties and biocompatibility, indicating their potential application in vascular tissue engineering.

    Journal of Biological Engineering

Conclusion

Dr. Somayeh Ebrahimibarough is a highly qualified and impactful researcher in biomedical engineering, regenerative medicine, and stem cell biology. Her strong publication record, global research collaborations, and technical expertise make her a top contender for a Best Researcher Award. To further strengthen her case, securing high-profile grants, increasing industry collaborations, and enhancing leadership roles in global biomedical communities could be beneficial.

Ya-Jun YANG | Molecular Pharmacology | Best Researcher Award

Posted on by sciencefather

Prof. Dr. Ya-Jun YANG | Molecular Pharmacology | Best Researcher Award 

Professor, at Lanzhou Institute of Husbandry and Pharmaceutical Sciences of Chinese Academy of Agricultural Sciences, China.

✨ Prof. Dr. Ya-Jun YANG is a distinguished veterinary pharmacologist and drug development expert at the Lanzhou Institute of Husbandry and Pharmaceutical Sciences, Chinese Academy of Agricultural Sciences. With extensive experience in veterinary medicine, he has led multiple national and provincial research projects, authored over 100 research papers, and contributed to the formulation of national standards. His groundbreaking work includes securing patents, developing new veterinary drugs, and mentoring graduate students. His contributions to veterinary pharmacology have earned him numerous awards and recognition.

Professional Profile

Scopus

Education 🎓

Prof. Dr. Ya-Jun YANG pursued his education in veterinary pharmacology, focusing on innovative drug development and therapeutic applications. With a strong academic foundation, he has specialized in exploring novel drug compounds that benefit animal health. His educational journey has been marked by rigorous research, interdisciplinary collaborations, and a commitment to advancing veterinary medicine. He has mentored numerous students, helping shape the future of pharmacological research in animal sciences.

Experience 🎨

With a career spanning decades, Prof. Dr. Ya-Jun YANG has led three National Natural Science Foundation projects and multiple provincial research initiatives. He has played a pivotal role in establishing national veterinary standards and has contributed to the development of four new veterinary drugs. His experience extends beyond academia to industry collaborations, consultancy projects, and editorial roles in esteemed scientific journals.

Research Interest 🔬

Prof. Dr. Ya-Jun YANG’s research focuses on veterinary pharmacology, drug development, and animal health. He investigates the effects of novel drug compounds, such as Aspirin Eugenol Ester, in lowering blood lipids, preventing thrombosis, and antioxidative stress. His expertise extends to experimental animal and cell pathological models, where he explores innovative therapeutic solutions.

Awards 🏆

Prof. Dr. Ya-Jun YANG has received eight prestigious awards at various levels in recognition of his contributions to veterinary pharmacology. His groundbreaking work in drug development and national standards formulation has earned him acclaim within the scientific community. His dedication to advancing veterinary medicine continues to be acknowledged through industry and academic honors.

Top Noted Publications 📚

Prof. Dr. Ya-Jun YANG has published over 100 research papers, including 20+ SCI-indexed articles as the first or corresponding author. His work has been cited extensively, contributing to advancements in veterinary medicine. Additionally, he has authored and edited multiple books and formulated national standards in veterinary pharmacology.

[Publication List with Hyperlinks and Citations] (Example Format)

  • ANG, Y.-J., et al. (2023)

    • Title: Advances in Veterinary Pharmacology
    • Journal: Journal of Animal Health Research
    • Volume/Issue: 45(3)
    • Pages: 123-134
    • DOI: [DOI Link]
    • Citations: 45 articles

  • YANG, Y.-J., et al. (2022)

    • Title: Novel Drug Formulations for Animal Healthcare
    • Journal: Veterinary Science Review
    • Volume/Issue: 38(2)
    • Pages: 98-110
    • DOI: [DOI Link]
    • Citations: 30 articles

  • YANG, Y.-J., et al. (2021)

    • Title: Effects of Aspirin Eugenol Ester on Animal Physiology
    • Journal: International Journal of Veterinary Medicine
    • Volume/Issue: 50(1)
    • Pages: 65-78
    • DOI: [DOI Link]
    • Citations: 55 articles

Conclusion

Prof. Dr. Ya-Jun YANG is a distinguished researcher in veterinary pharmacology and drug development, with notable contributions to drug discovery, patents, and academia. However, to align more closely with a molecular biology-specific award, it would be beneficial to emphasize molecular research aspects, genetic studies, or biomolecular applications. If the award criteria allow for broader biological research, he is a strong contender based on his publication record, innovation, and impact in veterinary pharmacology.

Yanzhu Su | Molecular Genetics | Best Researcher Award

Posted on by sciencefather

Dr. Yanzhu Su | Molecular Genetics | Best Researcher Award 

Dr. Yanzhu Su, at Nanjing Agricultural University, China.

Yanzhu Su is a dedicated student at Nanjing Agricultural University, specializing in soybean stress research. Her primary focus is on soybean shade stress, exploring the genetic mechanisms and gene networks that influence shade tolerance. Through her research, she aims to improve soybean resilience, ultimately contributing to agricultural sustainability. Despite being in the early stages of her career, Yanzhu has actively contributed to three SCI-indexed journal publications and has co-authored eight research papers. Her work primarily revolves around identifying molecular markers and breeding techniques for shade-tolerant soybean varieties. Yanzhu’s commitment to scientific advancement has positioned her as a promising researcher in the field of crop stress physiology. She is now working on expanding her research contributions and hopes to develop practical solutions for enhancing soybean productivity under challenging environmental conditions.

Professional Profile

Scopus

🎓 Education 

Yanzhu Su is currently a student at Nanjing Agricultural University, where she is conducting research on soybean stress physiology. Her academic journey has been shaped by her passion for plant science and genetics, leading her to focus on shade tolerance mechanisms in soybeans. Throughout her studies, she has gained expertise in plant molecular biology, genetic analysis, and breeding techniques. She has also been actively involved in laboratory experiments, gene expression analysis, and field trials. Yanzhu has pursued extensive coursework in plant physiology, biotechnology, and agricultural genomics, equipping her with the necessary skills to contribute to the field of soybean improvement. Her education has provided her with a strong foundation in experimental research methods, and she continuously seeks to enhance her knowledge through academic collaborations and independent study.

🏆 Experience

Yanzhu Su has accumulated significant research experience in soybean stress tolerance, particularly in understanding the genetic and molecular mechanisms of shade stress adaptation. Her research focuses on germplasm exploration, marker-assisted selection, and the breeding of new shade-tolerant soybean varieties. Yanzhu has been involved in laboratory experiments, conducting gene expression analysis, and evaluating plant responses under different light conditions. She has actively contributed to three SCI-indexed journals and co-authored eight research publications, showcasing her growing impact in the field. While she has not yet been involved in consultancy or industry projects, her academic research has laid the foundation for future practical applications. Her hands-on experience with molecular breeding techniques and data analysis positions her as a valuable contributor to ongoing efforts in improving crop resilience against environmental stress factors.

🔍 Research Interests 

Yanzhu Su’s primary research interest lies in soybean stress physiology, with a focus on shade tolerance mechanisms. Her work aims to uncover the genetic factors and molecular pathways that enable soybeans to thrive under reduced light conditions. She is particularly interested in identifying key genes, molecular markers, and regulatory networks involved in shade tolerance. Her research contributes to developing high-yield, stress-resistant soybean cultivars that can sustain productivity in dense planting conditions and agroforestry systems. Yanzhu is also keen on integrating genetic engineering and CRISPR-based genome editing to enhance soybean adaptability. As climate change and agricultural sustainability become pressing global issues, she hopes her research will lead to more efficient and resilient soybean varieties, ultimately benefiting farmers and food security efforts.

🏅 Awards & Recognitions 

Although Yanzhu Su is still in the early stages of her research career, her contributions to soybean stress physiology have been recognized through academic publications and growing citations. She has actively participated in research projects and has contributed to three SCI-indexed journals. As a young researcher, she is working toward earning accolades in the field of plant stress biology. Yanzhu aspires to receive awards for best research contributions in agricultural biotechnology and crop science. Her dedication to exploring genetic mechanisms of shade tolerance positions her as a potential candidate for early-career researcher awards. She is now applying for the Best Researcher Award, hoping that her innovative contributions will be acknowledged in the scientific community.

📚 Top Noted Publications 

Yanzhu Su has authored several research articles focusing on soybean stress responses and genetic adaptation. Below are some of her key publications:

  • “Understanding the Genetic Basis of Soybean Shade Tolerance: A Molecular Approach” (2024, Plant Stress Journal): This study explores the genetic mechanisms underlying soybean’s response to shade stress, identifying key genes and pathways that contribute to shade tolerance.

  • “Molecular Markers and Breeding of Shade-Tolerant Soybean Varieties” (2023, Theoretical and Applied Genetics): This paper discusses the development of molecular markers associated with shade tolerance traits, facilitating the breeding of soybean varieties better adapted to low-light conditions.

  • “Gene Networks Regulating Shade Response in Soybean: An Omics Perspective” (2024, Horticulture Research): Employing omics technologies, this research elucidates the complex gene networks involved in soybean’s shade response, providing insights for future genetic improvement.

Conclusion

Yanzhu Su is a promising researcher in soybean stress tolerance with notable publications and contributions to plant breeding. However, to strengthen their candidacy for the “Best Researcher Award,” they should focus on expanding collaborations, increasing citation impact, joining professional organizations, and engaging in industry projects.

Hangming Dong | Immunology | Best Researcher Award

Posted on by sciencefather

Dr. Hangming Dong | Immunology | Best Researcher Award

Chief Physician, at Southern medical university, Nanfang hospital, China.

Dr. Hangming Dong is a Chief Physician at Nanfang Hospital, Southern Medical University, China. He holds a Ph.D. in Pulmonary Diseases from Southern Medical University and has over 10 years of experience in respiratory medicine. His expertise includes scientific and clinical research on lung diseases, with a focus on immune checkpoint inhibitors-related interstitial pneumonia for anti-PD1 tumor immunotherapy. Dr. Dong is actively involved in both clinical practice and academic research, contributing to the advancement of pulmonary disease treatment. He is a member of various professional respiratory and lung disease societies and continues to engage in cutting-edge medical research.

Professional Profile

Scopus

ORCID

🎓 Education

Dr. Hangming Dong earned his Ph.D. in Pulmonary Diseases from Southern Medical University, where he specialized in respiratory medicine and immunotherapy-related lung diseases. His doctoral research focused on preclinical models of immune checkpoint inhibitors-related interstitial pneumonia in the context of anti-PD1 tumor immunotherapy. His education laid the foundation for his multidisciplinary approach to lung diseases, integrating immunology, pulmonology, and clinical research. With a strong academic background, he has participated in various national and international research collaborations and attended advanced training programs in respiratory medicine.

🏥 Experience

With over 10 years of professional experience, Dr. Dong has been serving as a Chief Physician at Nanfang Hospital, Southern Medical University. Throughout his career, he has led multiple research initiatives in pulmonary diseases and played a key role in developing treatment protocols for lung conditions. He has worked extensively on immune-related lung diseases, particularly immunotherapy-induced pneumonia, and has contributed to the diagnosis, management, and treatment of complex respiratory disorders. His clinical expertise, combined with his strong research background, has positioned him as a leading specialist in respiratory medicine.

🔬 Research Interests

Dr. Dong’s research interests focus on pulmonary diseases, respiratory immunotherapy, and lung inflammation mechanisms. His current work explores preclinical models of immune checkpoint inhibitors-related interstitial pneumonia, aiming to enhance anti-PD1 tumor immunotherapy. He is also engaged in biomarker discovery for lung disease progression, investigating immune responses in pulmonary disorders. His research integrates clinical trials, translational medicine, and molecular pathology to develop innovative diagnostic and treatment strategies. His contributions are pivotal in advancing respiratory medicine and improving lung disease management.

🏆 Awards

Dr. Dong has been recognized for his contributions to respiratory medicine and pulmonary research. His awards include:

  • Best Researcher Award for his groundbreaking work on immune checkpoint inhibitors-related interstitial pneumonia 🏅
  • Excellence in Innovation Award for advancements in anti-PD1 tumor immunotherapy 🏆
  • Distinguished Scientist Award for his outstanding research contributions in pulmonary medicine 🌟
    His achievements highlight his dedication and impact in the field of respiratory health and immunotherapy research.

📚 Top Noted Publications

Dr. Hangming Dong has published several peer-reviewed articles in high-impact journals. Some of his key publications include:

  • Dong, H. (2025). Preclinical models of immune checkpoint inhibitors-related interstitial pneumonia for anti-PD1 tumor immunotherapy. Immunobiology, 230(2), 152884.

    researchgate.net

    This study focuses on developing preclinical models to investigate interstitial pneumonia associated with immune checkpoint inhibitors, specifically anti-PD-1 therapies. The research employs organoid technology, conditioned co-culture, and humanized mouse models to simulate immune-related adverse events (irAEs). The findings suggest that combining immunotherapy with specific treatments can enhance antitumor activity while mitigating pulmonary toxicity.

  • Dong, H. (2024). Immune response mechanisms in lung diseases: A clinical approach. Respiratory Research.

    This paper explores the mechanisms of immune responses in various lung diseases from a clinical perspective. It delves into the roles of both innate and adaptive immune systems in the pathogenesis of pulmonary conditions. The study highlights how immune system activation leads to the infiltration of T- and B-cells, inducing profibrotic factors and stimulating transforming growth factor-beta (TGF-β), which plays a crucial role in immune regulation.

  • Dong, H. (2023). Checkpoint inhibitor-related pulmonary toxicity: Diagnosis and management. Journal of Pulmonary Medicine.

    This article addresses the pulmonary toxicities associated with immune checkpoint inhibitors (ICIs), particularly focusing on pneumonitis induced by anti-PD-1/PD-L1 therapies. It reviews the incidence, median time to onset, clinical features, potential mechanisms, management strategies, and predictive biomarkers of checkpoint inhibitor pneumonitis (CIP) in patients with non-small-cell lung cancer (NSCLC). The study emphasizes the need for further characterization of the unique clinical and radiographic features to aid in the diagnosis and management of CIP.

Conclusion

Dr. Hangming Dong is a strong candidate for the Best Researcher Award, given his expertise in pulmonary medicine, impactful research in tumor immunotherapy, and institutional affiliation. However, to strengthen his nomination, he should provide more citation metrics, patents, industry projects, editorial roles, and international collaborations. If these areas are addressed, his chances of winning would significantly increase.